Drugs / Ad4-H5-Vtn
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01806909 | Mar 2013 → Jan 2018 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT01443936 | Sep 2011 → Apr 2018 | avian influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT01006798 | Oct 2009 → Sep 2011 | avian influenza | Emergent BioSolutions | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad4-H5-VTN | “This is a Phase 1 randomized, single center, dose-escalation study designed to evaluate the safety and immunogenicity of live, replication competent recombinant Adenovirus type...” NCT01443936 ↗4“live, replication competent recombinant Adenovirus type 4-H5N1 Influenza Vietnam 1194 Hemagglutinin (HA) (Ad4-H5-Vtn)” NCT01806909 ↗ |
| Modality | Vaccine | “an oral adenovirus serotype 4 vector vaccine candidate (Ad4-H5-Vtn) expressing the haemagglutinin from an avian influenza A H5N1 virus” PMID 23369412 ↗ Jan 2013 |
| Route | Oral | “for oral administration” NCT01006798 ↗ |